医学
围手术期
肺癌
临床试验
重症监护医学
靶向治疗
肿瘤科
内科学
癌症
生物信息学
外科
生物
作者
Siyang Liu,Si‐Yang Maggie Liu,Wen‐Zhao Zhong,Yi‐Long Wu
标识
DOI:10.1007/s11864-022-00994-w
摘要
Tyrosine kinase inhibitors (TKIs) have dramatically improved tumor response rates and survival benefits in advanced oncogenic non-small-cell lung cancer (NSCLC). Given the impressive success, a renewed interest has been raised in the study of these agents in the perioperative setting. Preliminary data have shown dramatic effectiveness compared to conventional chemotherapy. Given the explicit need to induce durable responses and raise cure rates, we summarize the current progression, identify key challenges, and raise potential opportunities for perioperative targeted therapy that range from precise biomarkers to optimal adjuvant regimens for individual patients. As perioperative treatment indeed provides researchers with a unique platform to address the challenges mentioned above, investigators could obtain a comprehensive analysis of genomic profiling and trace resistance mechanisms. Multidisciplinary collaboration and adaptive clinical trial designs are warranted to integrate translational research into personalized perioperative TKI treatment paradigms.
科研通智能强力驱动
Strongly Powered by AbleSci AI